azathioprine.ppt
DESCRIPTION
azathoprine- renal transplantTRANSCRIPT
![Page 1: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/1.jpg)
AZATHIOPRINE
![Page 2: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/2.jpg)
• Class: Immunosuppressive,an analogue of mercaptopurine
• Action Suppresses cell-mediated hypersensitivities; alters antibody production and may reduce inflammation.
![Page 3: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/3.jpg)
• Indications Adjunct for prevention of rejection in renal homotransplantation; treatment in adults for severe, active, erosive rheumatoid arthritis not responsive to conventional management.
• Unlabeled use(s): Treatment of chronic ulcerative colitis, Crohn's disease, myasthenia gravis and Behcet's syndrome
• Contraindications Pregnancy in patients with rheumatoid arthritis
![Page 4: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/4.jpg)
Route/Dosage
• Renal Transplantation• ADULTS & CHILDREN: IV/PO Initiate with 3 to
5 mg/kg/day as single daily dose. Maintenance levels are 1 to 3 mg/kg/day.
![Page 5: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/5.jpg)
• Rheumatoid Arthritis
• ADULTS: PO Initial dose is 1 mg/kg given as single dose or twice daily. Dose is increased by 0.5 mg/kg/day at 6 to 8 wk, then every 4 wk if there are no serious toxicities and if initial response is unsatisfactory.
• Max dose is 2.5 mg/kg/day. IV Reserved for patients unable to tolerate oral medications.
![Page 6: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/6.jpg)
• Adverse Reactions
• DERM: Rash. GI: Nausea; vomiting.• HEMA: Leukopenia; thrombocytopenia;
macrocytic anemia; bleeding; selective erythrocyte aplasia.
• OTHER: Serious infections; neoplasias.
![Page 7: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/7.jpg)
• Interactions• Allopurinol• Nondepolarizing muscle relaxants (eg,
tubocurarine, pancuronium)
![Page 8: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/8.jpg)
Precautions
• Pregnancy: Category D.• Lactation: Excreted in breast milk. • Children: Safety and efficacy not established. • Carcinogenesis/mutagenesis• GI toxicity• Hematologic effects• Superinfection
![Page 9: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/9.jpg)
NURSES RESPONSIBILITY
• Administration/Storage• Do not vigorously shake solution when
reconstituting IV preparations. • Divide daily dosage to reduce GI upset. • Administer with food or immediately after meals. • Store in a tightly-closed container in a cool location. • Discard reconstituted IV preparations after 24 hr.
Follow any procedures required for proper disposal of immunosuppressant/antimetabolite
![Page 10: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/10.jpg)
Assessment/Interventions
• Obtain patient history, including drug history and any known allergies.
• Review baseline CBC, renal studies and liver studies. • Assess for signs of infection before administration. • Monitor I&O and daily weight during therapy. • Monitor patient for signs of superinfection during
therapy. • Notify physician if patient displays sudden, severe
dyspnea, bleeding from the gums or mucous membranes or blood in urine or stools.
![Page 11: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/11.jpg)
• Instruct patient that if once-daily dose is forgotten to skip the dose, but if 2 daily doses are missed to call the physician. Next dose may be doubled.
• Explain importance of precautions regarding contact with individuals who have active infections and individuals who have recently received oral polio vaccine.
• Identify signs of transplant rejection
![Page 12: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/12.jpg)
• Explain that frequent follow-up appointments• Instruct patient to report the following
symptoms to physician: Unusual bleeding, decreased urine output, abdominal pain.
• Caution patient not to take otc medications without consulting physician
![Page 13: Azathioprine.ppt](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5563b610d8b42ac70d8b4f23/html5/thumbnails/13.jpg)
Thank you ……………..